Chonluten
T-34 · EDG tripeptide · Glu-Asp-Gly · H-Glu-Asp-Gly-OH · Glutamyl-aspartyl-glycine
Last updated
At a glance
Overview
Why Chonluten Is on the Radar#
Chonluten is the bronchopulmonary entry in the Khavinson short-peptide catalog — a three–amino-acid sequence (Glu-Asp-Gly) that sits alongside Epitalon, Vilon, and Bronchogen in the Russian geroprotection toolkit. The community reaches for it for one reason: it's the cleanest tool available for dampening epithelial inflammation and restoring bronchial tissue without touching the HPG axis, without requiring PCT, and without the felt-effect volatility of GH-axis peptides. Post-COVID recovery, ex-smoker lung rehab, and on-cycle cytokine management are where it earns its keep.
Mechanistically, EDG is proposed to enter cell nuclei and modulate transcription directly — shifting SOD and other antioxidant gene expression, suppressing TNF-α and IL-6 output in activated monocytes, and nudging macrophage polarization via STAT1/STAT3 balance. Critically, the TNF-α suppression was independently reproduced outside the St. Petersburg group in a THP-1 model, which is rare for this peptide family and worth weighting heavily.
"The EDG peptide at nanomolar concentrations significantly reduced TNF-alpha release from LPS-stimulated THP-1 monocytes, supporting an anti-inflammatory effect." — Avolio et al., Int J Mol Sci (2022)
What follows covers the canonical 10–20 day Khavinson protocol, SubQ dosing in the 200–500 mcg conservative range versus the milligram-range community extrapolations, reconstitution math for the standard 20mg vial, stacking logic with Bronchogen and Epitalon, and where the evidence base is genuinely solid versus where it's a single-lab story. The goal is a coherent quarterly course — not a chronic daily habit.
How Chonluten works
Peptide–DNA Interaction and Tissue-Specific Transcription#
Chonluten (Glu-Asp-Gly, "EDG") belongs to the Khavinson family of short-peptide bioregulators — 2–7 amino acid sequences hypothesized to enter cell nuclei and dock directly with specific promoter regions of DNA, modulating transcription of tissue-selective gene programs. EDG shows organ-preferential activity in bronchopulmonary epithelium and, secondarily, gastric mucosa, which is why the compound is positioned as a "lung bioregulator" rather than a systemic signalling peptide.
"Short peptides including Glu-Asp-Gly are proposed to modulate transcriptional activity by directly interacting with specific regions of DNA in target cells." — Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Molecules, 2020
The practical consequence is that effects are cumulative and gene-expression-driven rather than acute. There is no "felt" dose — no GH-like flush, no dopaminergic kick. Benefits, where present, accrue over a 10–20 day course and persist beyond plasma clearance because the downstream transcripts and protein pools have been reset.
Cytokine Dampening in Monocytes and Macrophages#
The most externally-validated mechanism for EDG is modulation of the STAT1/STAT3 axis in activated monocytes. The tripeptide promotes STAT1 phosphorylation while suppressing STAT3 phosphorylation, with downstream reduction in TNF-α, IL-6, and IL-17 output. This is the closest thing EDG has to a replicated finding outside the St. Petersburg group.
"The EDG peptide at nanomolar concentrations significantly reduced TNF-alpha release from LPS-stimulated THP-1 monocytes, supporting an anti-inflammatory effect." — Avolio F, Martinotti S, Khavinson VKh, et al. International Journal of Molecular Sciences, 2022
For the physique-focused reader, this is the mechanistic rationale behind the "on-cycle anti-inflammatory adjunct" use case. Heavy oral AAS and high-hematocrit cycles push hs-CRP and IL-6 upward; a 10–20 day EDG course at 500–1,000mcg is used as a low-footprint cytokine-modulating layer on top of standard hematocrit and lipid management. It is not a substitute for donating blood, managing BP, or running a proper ancillary — it is a margin tool.
Antioxidant Gene Regulation (SOD, Redox Defence)#
EDG normalizes expression of superoxide dismutase (SOD) and related redox-defence transcripts in stressed epithelial tissue. In models of mucosal injury, the peptide shifts the oxidative balance back toward baseline rather than acting as a direct free-radical scavenger — a transcriptional effect rather than a stoichiometric one.
"Specific peptides, including Glu-Asp-Gly, normalized SOD gene expression and reduced pro-inflammatory cytokine levels in epithelial tissue models." — Khavinson VKh, Lin'kova NS, Dudkov AV, Polyakova VO, Kvetnoy IM. Bulletin of Experimental Biology and Medicine, 2012
Practical readout: EDG's antioxidant effect is epithelial-weighted, not systemic. The bronchial lining of someone with post-COVID sequelae, years of vape exposure, or chronic high-volume conditioning work is the tissue most likely to register the shift. Full-body "antioxidant peptide" framing overstates what the literature actually supports.
Fibroblast Proliferation, Angiogenesis, and Epithelial Restoration#
Beyond cytokine dampening, EDG upregulates proliferative repair programs in damaged epithelium — stimulating fibroblast proliferation, angiogenesis, and reconstruction of bronchial epithelial architecture after injury. Modulation of c-Fos, COX-2, and HSP70 has been reported in the same model systems.
"Peptide bioregulators can stimulate fibroblast proliferation, improve angiogenesis, and restore bronchial epithelial structure after injury." — Khavinson VKh, Solovyev AY, Tarnovskaya SI, Lin'kova NS. Lung, 2014
This is also the mechanism that makes active respiratory or gastric epithelial malignancy a hard contraindication. The same proliferative, anti-apoptotic, pro-angiogenic gene programs that restore injured mucosa overlap with tumor survival biology, and no human oncology safety data exists to bound that risk.
Senescence Attenuation in Mesenchymal Stem Cells#
In vitro work from the Khavinson group reports extension of mesenchymal stem cell (MSC) replicative lifespan and attenuation of senescence-associated markers on EDG exposure. This is the mechanistic foothold for EDG's inclusion in the canonical geroprotection rotation alongside Epitalon (AEDG, pineal), Vilon (KE, thymic), and Cerluten (cortical) — EDG occupies the bronchopulmonary slot in that full-body peptide cycle.
Credibility caveat worth stating plainly: the overwhelming majority of mechanistic data on EDG is authored by the St. Petersburg Institute of Bioregulation and Gerontology. External replication is limited to the Avolio 2022 THP-1 macrophage work.
"Avolio et al. (2022) provide rare independent confirmation of EDG's cytokine-dampening effect, while most findings remain St. Petersburg–originated." — Rapamycin.news independent validation panel, 2026
Translation for the reader: EDG's anti-inflammatory effect on activated monocytes is the mechanism with the strongest evidentiary floor. The transcriptional, angiogenic, and senescence-attenuation claims are mechanistically coherent and internally consistent across the Khavinson catalog, but the external replication pipeline is thin. Dose conservatively, run the canonical 10–20 day course, and don't extrapolate beyond what the published protocol supports.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 100–500 mcg | Once daily | Documented entry-level range |
| Mid | 500–1500 mcg | Once daily | Most commonly studied range |
| High | 2000–4000 mcg | Once daily | Canonical protocol: once-daily SubQ for 10–20 consecutive days, repeated every 3–6 months. Conservative community consensus tracks the published Russian protocol at 200–500mcg SubQ daily × 10–20 days. |
Cycle length & outcomes
Documented cycle
2–3 weeks
Plateau after
3 wks
Cycle Notes#
Chonluten doesn't cycle like a steroid or even like a growth peptide. It's a Khavinson-class short-peptide bioregulator, which means its proposed mechanism — direct peptide–DNA interaction driving transcriptional shifts in bronchial and gastric epithelium — produces effects that outlast plasma clearance by weeks or months. The canonical Russian protocol is a short course repeated quarterly, not chronic daily use.
Standard Protocol: The 10–20 Day Khavinson Course#
The foundational cycle is 10–20 consecutive days of once-daily SubQ administration, repeated every 3–6 months. This is the pattern the original clinical literature is built on and the one that matches the hypothesized "gene-expression pulse" mechanism. Longer daily courses have no published efficacy advantage and are not supported by dose-response data.
| Goal | Cycle Length | Daily Dose (SubQ) | Repeat |
|---|---|---|---|
| Post-respiratory-insult recovery (post-COVID, ex-smoker, post-bronchitis) | 10–20 days | 200–500 mcg | Every 3–6 months |
| On-cycle cytokine dampening (heavy AAS, elevated hs-CRP/IL-6) | 10–20 days | 500–1,000 mcg | Once per blast |
| Endurance / cardio-respiratory support during conditioning blocks | 10 days | 500 mcg | As needed |
| Gastric mucosal support (hard orals + NSAIDs) | 10–14 days | 500 mcg | Per oral cycle |
| Khavinson geroprotection rotation (with Epitalon, Vilon, Cerluten) | 10–20 days | 200–500 mcg | Twice yearly |
The conservative community consensus — and the one that tracks the published protocol most closely — is 200–500 mcg SubQ once daily for 10–20 days. Multi-milligram titration schemes circulated by some dosing calculators are extrapolations from vial size, not study-validated ranges.
Onset and Expected Timeline#
EDG is not a felt compound. There is no dopaminergic kick, no GH-like flush, no pump. The mechanism is transcriptional, so changes accumulate:
- Days 1–5: nothing subjective. This is normal and not a signal to dose higher.
- Days 7–14: early endpoints shift in the documented use-cases — reduced cough frequency, improved breathing comfort under load, reduced epigastric discomfort on orals.
- Weeks 2–6 post-course: the bulk of the transcriptional effect plays out after the final injection, which is why 3–6 month spacing is standard rather than continuous dosing.
Anyone expecting acute felt effects within 48 hours is reading the wrong compound class.
Tapering and Loading#
Neither is required. EDG has no HPG-axis involvement, no receptor downregulation pattern to worry about, and no withdrawal signature. Start at the protocol dose, run the 10–20 days, stop. No taper, no PCT, no bridge.
A very mild histamine-type flush or transient malaise has been anecdotally reported across the Khavinson family on the first 1–2 doses — if that shows up, starting at the low end of the range (200 mcg) for the first three days and stepping up to the target dose is reasonable. It's not a safety-driven ramp, just a comfort one.
Bloodwork Cadence#
No bloodwork is strictly required. EDG is not hepatotoxic, not hematologic, not endocrine-active. For users running it for the cytokine-dampening use-case, the useful panel is:
- hs-CRP, IL-6 — baseline and 2–4 weeks post-course; the mechanistic basis is the TNF-α/IL-6 attenuation documented in LPS-stimulated monocytes.
- CBC with differential — mainly relevant if EDG is layered onto a heavy AAS protocol where hematocrit is already being tracked.
"The EDG peptide at nanomolar concentrations significantly reduced TNF-alpha release from LPS-stimulated THP-1 monocytes, supporting an anti-inflammatory effect." — Avolio et al., International Journal of Molecular Sciences (2022)
For the respiratory use-case, subjective endpoints (peak flow, exercise breathing comfort, cough frequency) are the community norm and frankly more responsive than serum markers.
Stacking Within a Cycle#
EDG plays well inside a broader protocol because it has no overlapping receptor targets with anabolics, GH-axis peptides, or repair peptides like BPC-157.
- + Bronchogen (AEDL): the canonical "lung stack" — two bronchial-targeted Khavinson peptides run in parallel 10–20 day courses for complementary airway gene-expression targets.
- + Epitalon (AEDG): systemic geroprotection pairing — EDG covers the bronchopulmonary axis, AEDG the pineal/telomere axis.
- + BPC-157: broad epithelial and mucosal repair coverage, particularly useful alongside hard orals or aggressive cuts.
- + CJC-1295 / Ipamorelin or tesamorelin: no interaction concerns; EDG runs as a short mini-course inside a longer GH-peptide block.
"Peptide bioregulators can stimulate fibroblast proliferation, improve angiogenesis, and restore bronchial epithelial structure after injury." — Khavinson et al., Lung (2014)
Repeat Frequency#
Quarterly is the default. Twice-yearly is the minimum useful cadence in the geroprotection context. Running EDG continuously or back-to-back courses with no washout has no published rationale and contradicts the Khavinson pulsed-dosing framework — save the vials for the next scheduled course.
One hard note worth repeating: EDG upregulates proliferative and anti-apoptotic gene programs (HSP70, fibroblast proliferation, angiogenesis). Active malignancy — particularly respiratory or gastric epithelial — is a hard contraindication until human oncology safety data exists, which it does not. That constraint doesn't change with cycle length or dose.
Risks & mistakes
Common (most users)#
Chonluten is one of the cleaner-tolerated peptides in the Khavinson catalog. Most users complete a 10–20 day course without noting anything beyond the usual SubQ housekeeping.
- Injection-site redness, mild sting, or transient bruising — standard for any SubQ peptide. Rotate between lower abdomen, flank, and thigh; warm the reconstituted vial in the hand before drawing to reduce sting.
- Mild flush or brief malaise in the first 1–2 doses — anecdotally reported across the Khavinson family. Usually self-limiting within 48 hours; dose at night if it's disruptive.
- Nothing felt at all — the most common "side effect." EDG works via transcriptional shifts that accumulate over the course rather than a dopaminergic or GH-like acute hit. Absence of a felt effect on day 1–3 is normal and does not indicate an underdose.
- Minor injection-site lumps at higher SubQ volumes — reconstitute 20 mg vials in 2 mL (10 mg/mL) rather than 3 mL so the 200–500 mcg dose lands in a smaller injection volume.
Uncommon (dose-dependent or individual)#
These track with the multi-milligram community titration protocols rather than the published 200–500 mcg range. Most are inferred from the Khavinson family's general signal rather than EDG-specific reports.
- Prolonged flush or headache at 2–4 mg SubQ — back off to the conservative 500 mcg tier; the published dose–response evidence does not support the higher range as more effective.
- Transient GI unsettlement — more often reported with the encapsulated oral preparation than with SubQ. Administer with food if using the oral format.
- Mild fatigue or sleep disruption in the first few days — usually resolves by day 5–7. If it persists, shift dosing to morning.
- Elevated subjective sensitivity in allergy-prone users — anyone with prior reactions to short peptides should start at 100 mcg SubQ for the first two doses and titrate up only if clean.
No characteristic bloodwork derangement has been attributed to EDG. For users running longer courses or stacking across the full Khavinson catalog, a pre/post hs-CRP, IL-6, and CBC is sensible — both to track the intended anti-inflammatory signal and to rule out anything unexpected.
Rare but serious#
No serious adverse events are documented in the indexed EDG literature. The items below are mechanistic cautions rather than reported incidents — the honest position is that external safety data is thin, with the Avolio 2022 THP-1 work being one of the few non-Khavinson-group confirmations of the compound's biology at all.
"The EDG peptide at nanomolar concentrations significantly reduced TNF-alpha release from LPS-stimulated THP-1 monocytes, supporting an anti-inflammatory effect." — Avolio et al., Int J Mol Sci, 2022
- Systemic hypersensitivity reaction — urticaria, wheeze, facial swelling. Discontinue immediately and do not rechallenge.
- Unexpected acceleration of a pre-existing epithelial lesion — EDG upregulates proliferative and anti-apoptotic programs (HSP70, fibroblast proliferation, angiogenesis). In a user with an undiagnosed respiratory or gastric epithelial malignancy, the same signal that rebuilds healthy mucosa could plausibly support tumor biology. New or worsening cough, hemoptysis, persistent dyspepsia, or melena during a course is a reason to stop and get imaged.
- Blunted response to an acute infection — the TNF/IL-6 dampening that's therapeutic in chronic low-grade inflammation is not desirable during active sepsis or cytokine storm. Pause the course if a serious acute infection develops.
Hard contraindications#
These lines do not get crossed. The evidence base is too thin to hedge.
- Active malignancy, particularly respiratory epithelial or gastric cancer. EDG's documented effects on fibroblast proliferation, angiogenesis, and anti-apoptotic gene expression overlap meaningfully with tumor survival biology (Khavinson 2014, Lung).
- Acute bacterial or viral infection with active cytokine storm. Protocols run EDG during recovery, not during acute immune activation.
- Known hypersensitivity to short-peptide bioregulators. Prior systemic reaction to any Khavinson-family peptide is disqualifying.
- Pregnancy and lactation. No data. Exclude.
Gender, PCT, and special populations#
No sex-specific signals appear in the EDG literature. Dosing is not bodyweight-scaled and applies uniformly across the subject pool — the 200–500 mcg SubQ range is identical for male and female users. No virilization risk, no effect on the HPG axis, no effect on menstrual cycling documented.
PCT: not required. EDG does not suppress endogenous testosterone, LH, FSH, or any HPG-axis hormone, and it has no documented estrogenic or androgenic activity. It stacks freely alongside AAS cycles, SARMs, or PCT protocols without adding to the ancillary burden.
Conception planning: no reproductive toxicology data exist. Users actively trying to conceive or gestating should exclude the compound on precautionary grounds rather than documented harm.
Stacking interactions: no known pharmacological interactions with AAS, GH secretagogues, BPC-157, TB-500, or the rest of the Khavinson catalog. The main stacking caution is cognitive, not pharmacological — running five Khavinson peptides simultaneously makes it impossible to attribute any outcome to any single compound. Rotate 2–3 per quarter.
FAQ — Chonluten
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy Chonluten, 20mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Chonluten
Research & citations
5 studies cited on this page.
Conclusion
Chonluten slots into the short-peptide longevity toolkit as a bronchopulmonary bioregulator with an anti-inflammatory and pro-repair signature. While most mechanistic evidence is Russian in origin, external replication of cytokine-dampening effects adds weight to its profile.
Key takeaways:
- Canonical protocol: 200–500 µg SubQ daily for 10–20 days, repeated every 3–6 months
- Functional mechanism: transcription-level modulation of antioxidant and anti-inflammatory genes (Khavinson 2012; Avolio 2022)
- Best-use cases: post-respiratory-recovery, long-haul COVID, on-cycle inflammation, or as part of a Khavinson peptide rotation for organ-specific support
- Stacking: often paired with Bronchogen (AEDL) for enhanced bronchial repair or Epitalon for systemic geroprotection
- No PCT requirement, no known endocrine suppression, and minimal reported side effects at research doses
For users structuring a longevity or recovery-phase protocol and prioritizing epithelial and bronchial tissue support, Chonluten offers a practical, low-risk addition — especially in short, pulsed courses backed by the established protocol.